AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2018
May 15, 2018
31523_dirs_2018-05-15_efe68ca1-2337-4a71-ac06-9ff5b965144e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-05-14
Reporting Person: Barth Jay (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-05-14 | Common Stock | M | 5000 | $2.29 | Acquired | 90409 | Direct |
| 2018-05-14 | Common Stock | S | 5000 | $14.0445 | Disposed | 85409 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-14 | Stock Options (right to buy) | $2.29 | M | 5000 | Disposed | 2024-03-03 | Common Stock (5000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 125 | Indirect |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.95 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: All of the options were fully vested and exercisable as of May 14, 2018.